13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773195
Total reported value
$2.2B
$2.2B
84 檔
9.2%
The Q3 2024 SEC filing reveals that Affinity Asset Advisors, LLC held a total portfolio value of $2.2B, covering 84 public equity positions.
During Q3 2024, Affinity Asset Advisors, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 6.15% | -0.68% | +15.07% | |
| 2 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 5.90% | -1.61% | -7.69% | |
| 3 | FLNA | Filana Therapeutics Inc | Stock-Other | 5.82% | — | — | |
| 4 | APGE | Apogee Therapeutics Inc | Stock-Other | 5.32% | +0.33% | -20.58% | |
| 5 | NUVL | Nuvalent Inc-a | Stock-Other | 4.71% | -0.05% | +68.75% | |
| 6 | ACLXGBX | Arcellx Inc | Stock-Other | 4.56% | -2.15% | EXIT | |
| 7 | ALKS | Alkermes plc | Stock-Healthcare | 3.82% | +0.79% | +53.85% | |
| 8 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 2.90% | -0.52% | -9.09% | |
| 9 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.79% | -0.01% | -22.33% | |
| 10 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.64% | +0.29% | -5.66% | |
| 11 | VERA | Vera Therapeutics Inc | Stock-Other | 2.62% | -0.04% | +16.00% | |
| 12 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.55% | — | -7.14% | |
| 13 | AUTL | Autolus Therapeutics PLC | Stock-Other | 2.23% | — | +4.65% | |
| 14 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.11% | -2.87% | EXIT | |
| 15 | ✓ | Inozyme Pharma Inc | Stock-Other | 2.01% | — | -1.19% | |
| 16 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.00% | +1.80% | -2.92% | |
| 17 | OMER 5.25 02-15-26Bond | Omeros CORP | Bond | 2.00% | — | +87.99% | |
| 18 | KURA | Kura Oncology Inc | Stock-Other | 1.83% | — | +5.81% | |
| 19 | CHRS 1.5 04-15-26Bond | Coherus Oncology Inc | Bond | 1.78% | — | +41.49% | |
| 20 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.72% | +0.28% | +30.01% | |
| 21 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.63% | -0.04% | +250.00% | |
| 22 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.57% | -0.52% | EXIT | |
| 23 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.31% | — | +25.64% | |
| 24 | IMVT | Immunovant Inc | Stock-Other | 1.18% | +0.04% | -24.32% | |
| 25 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.17% | +1.27% | — | |
| 26 | RZLT | Rezolute Inc | Stock-Other | 1.13% | — | -8.11% | |
| 27 | ✓ | Merus N V | Stock-Other | 1.10% | — | +29.39% | |
| 28 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.09% | — | -25.68% | |
| 29 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.07% | — | -68.18% | |
| 30 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.07% | -0.03% | +11.64% | |
| 31 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.04% | -0.58% | EXIT | |
| 32 | CLYM | Climb Bio Inc | Stock-Other | 1.04% | +0.32% | -10.22% | |
| 33 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.98% | — | — | |
| 34 | ERAS | Erasca Inc | Stock-Other | 0.93% | -0.12% | — | |
| 35 | GERN | Geron CORP | Stock-Other | 0.93% | — | — | |
| 36 | ANAB | Anaptysbio Inc | Stock-Other | 0.91% | -0.17% | — | |
| 37 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.91% | -0.03% | -9.09% | |
| 38 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.86% | -0.10% | +550.00% | |
| 39 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.79% | — | — | |
| 40 | PCVX | Vaxcyte Inc | Stock-Other | 0.78% | — | -33.33% | |
| 41 | ARVN | Arvinas Inc | Stock-Other | 0.76% | — | — | |
| 42 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.68% | -1.53% | EXIT | |
| 43 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.64% | — | +110.72% | |
| 44 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.60% | +0.15% | — | |
| 45 | TVTX 2.25 03-01-29Bond | Travere Therapeutics Inc | Bond | 0.59% | — | — | |
| 46 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.58% | +0.36% | -73.71% | |
| 47 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.58% | -0.14% | +6.72% | |
| 48 | NVAX | Novavax Inc | Stock-Healthcare | 0.52% | — | — | |
| 49 | INSM | Insmed Inc | Stock-Healthcare | 0.50% | -0.92% | -62.60% | |
| 50 | ✓ | Stock-Other | 0.48% | — | — |
According to official SEC Form 13F filings, Affinity Asset Advisors, LLC reported a total U.S. public equity portfolio value of $2.2B across 84 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XENE, TEVA, FLNA) accounted for 9.2% of total reported equity market value during Q3 2024.
During Q3 2024, Affinity Asset Advisors, LLC's top holdings by market value included XENE (6.2%)、TEVA (5.9%)、FLNA (5.8%). The largest single position, XENE, represented 6.2% of total portfolio value.
In Q3 2024, Affinity Asset Advisors, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.